LATEST NEWS

November 21th, 2017 Moscow, Russia and Pully, Switzerland:  Nativa LLC and CarthaGenetics® announce collaboration in North Africa area

nativa

Nativa LLC is a full-cycle Russian pharmaceutical company founded in 2010, developing and producing world-class complex medicaments essential for human health. It focuses on oncology, pulmonology, multiple sclerosis and other fields.

CarthaGenetics® is focusing on finding innovative early patients access to medicines for treating unmet needs and is now a pioneer with one of the broadest experience in the field of rare diseases, gene therapies and biosimilars.

For any question concerning this please contact Vladimir A. Mefodovskiy, CDO at Nativa LLC v.mefodovskiy@nativa.pro or Philippe Carteron de Balmont CEO, at CarthaGenetics® phcarteron@carthagenetics.com

Results of the Survey about the Factors Impacting on Community Pharmacy Efficiency

bursa tebTurkish health sector has been changed completely with the Health Transformation Project lead by Ministry of Health. In this process of change, healthcare providers have become more competitive in healthcare market. As a result of project the health expenditures has been

increased and policy makers implemented policies for controling this increase. These policies made the competitive environment even more challenging. Community pharmacy, one of the most important actors of the healthcare sector and one of the first steps in the health service access of the society, confronts many difficulties, especially financial in this competitive and challenging market. Despite these difficulties, community pharmacists continue to practice for community pharmacy is a profession, an art, and a doing good. In this process, it is necessary to evaluate the difficulties of community pharmacists and what needs to be done to cope with these difficulties. The study that emerged from this point of view was made by Bursa Pharmacist Chamber through CarthaGenetics Consulting firm. While trying to assess the efficacy of free pharmacists in the study, it was aimed to identify the concerns for sustainable pharmacy and to find possible recommendations for them. We hope that the study will shed light on the Turkish pharmacy community and form the basis for further studies.
Pharmaceutical Market Access in Developed Market is now pre-order on Amazon!!

418n2QP6f5LThe book titled as “Pharmaceutical Market Access in Developed Markets” under Dr. Guvenc Kockaya (CarthaGenetics market Access Director) and Prof. Albert Wert heimer’s editorialship has been published for pre-order on Amazon.

Market access is the process by which a pharmaceutical company gets its product available on the market after having obtained a marketing authorization from a regulatory agency and by which the product becomes available for all patients for whom it is indicated as per its marketing authorization. Since there are cultural differences among countries, any Market Access strategy needs to be culturally sensitive. Pharmaceutical Market Access in emerging markets has been extensively discussed in the previous book, published in 2016. The present book focuses on developed markets with the goal of helping students, academics industry personnel and government workers and decision makers understand the environment in developed markets.

Health Technology Assessment Report about Hypertermic Intraperitoneal Chemotherapy (HIPEC)
sb_logo_6uDraft HTA report about HIPEC under Dr. Guvenc Kockaya`s authorship has been published by Ministry of Health of Turkey. The report will be online up to 9th November 2017 for getting comments from community. The final report will be published after review of comments.
Keep track, keep contact. For further questions: kockaya@carthagenetics.comsharaf@carthagenetics.com
Monday September 4th – Exciting News from Spain !
Photo buiding Regus Cuzco

As a growing company, a new chapter has begun for CarthaGenetics® Iberica.

You can now find us from today at our new location at: CarthaGenetics® Iberica Paseo de la Castellana 141, Cuzco IV, 28046 Madrid Spain. Telephone: +34 91572 6644 Email: madrid@carthagenetics.com. Do not hesitate to contact us!

May 16th, 2017 – CarthaGenetics® will be working on three projects in Turkey in support of governmental healthcare priorities

The-Ministry-of-Health---Turkey-600px-logoCarthaGenetics®, who enjoys a multiyear presence in Turkey with a team of market access experts, is committed to supporting government and non-government authorities with building health economics and health technology assessment (HTA) environments, leading to a solid and sustainable healthcare system. In this context, CarthaGenetics® announced today that it had signed an agreement with the Turkish Ministry of Health to drive and implement three different projects to support the diverse governmental healthcare priorities.

In the first agreement signed with the Ministry of Health of Turkey, CarthaGenetics® will prepare a comprehensive health technology report on the Importance, Development and Production of Disposable Circumcision Instruments in collaboration with local partner Turkiye Klinikleri. This project will roll out over a period of 10 months with 8 Turkey-based local experts and will deliver hands-on recommendations to the Ministry.

The second agreement signed between the CarthaGenetics® market access expert team and the Ministry of Health will lead to preparing a brief health technology report on the key topic of Hyperthermic Intraperitoneal Chemotherapy (HIPEC)”. This project will roll out over a period of 7 months and will provide key directions to public decision makers of Turkey.

Finally, CarthaGenetics® will be conducting a regional survey for Bursa Ecza Odası in collaboration with Dr. Gulpembe Ergin in order to understand “Factors impacting the efficiency of pharmacy practice”. This study, initially focused on Bursa-based pharmacies, is meant to later model the way for all pharmacies across the country. This survey, recently kicked off, will be active until June 25th, 2017 and final results will be published in relevant congresses and journals.

For more information about these projects, please contact Güvenç Koçkaya, International Market Access Director, CarthaGenetics® at: kockaya@carthagenetics.com

May 2nd, 2017! Milestone for Imported Drugs in Turkey!
unnamedTurkish Social Security Institute is taking over the drug procurement procedure (for unauthorized and orphan drugs) as of May 2nd!
In the last days of December 2016, Turkish Social Security Institute (SGK) announced that the institute will take over the procedure of drug procurement. Until now, this was managed by the Turkish Pharmacists Association (TEB). TEB was the only body entitled to import these drugs and had a well-set organization for the purchasing and distribution of the drug to the patient.
SGK changed its organizational structure and established a unit specifically for the procurement of unauthorized drugs in Turkey. As of May 2nd, SGK will be the main body to import these drugs. In order to have a smooth transition for the sake of the patients, SGK signed a contract with TEB for a certain period of time.
According to the new system, the cold-chain products will continue to be provided by TEB for the coming few months. Meanwhile, SGK is ensuring that adequate number of personnel are recruited and trained for its warehouse. The brand-new products that will enter the market for the 1st time will directly be procured by SGK.
Do not hesitate to contact us for any information at kaya@carthagenetics.com !
BIG CHANGES are on the way for the off-label drug procurement in Turkey!

unnamed

Turkish Social Security Institute (SGK) made structural changes to take over the procurement of drugs without market authorization in Turkey from TEB (Turkish Pharmacists Association). SGK will import these products, which are under Named Patient Sales Program in Annex 4C, as of May 2nd, 2017. They have a new system where prices are being reviewed again.

We, CarthaGeneticsÒ Team, provide services to companies who want to be a part of the current and upcoming NPS market access process in Turkey. For more information, you can reach us at kaya@carthagenetics.com

Turkey is one of the countries in Europe and Middle East with the highest number of population (80 million) and gathers all its citizens under the umbrella of the government health insurance system. This seems to bring a real burden on the social security system. To use the healthcare budget, ministry gathers prices from 5 European countries as reference and takes the lowest price for pricing calculations. With the obligatory discounts and fixed exchange rate, getting a market authorization for a drug in Turkey means 65% discount for the manufacturer.

On the other hand, being one of the rare countries with a broad social security coverage, Turkey opens its doors wide to rare diseases and orphan drugs. Rate of consanguineous marriages being 22%, Turkey seems to be hosting rare diseases more than many other countries.

For unauthorized drugs and orphan drugs, TEB (Turkish Pharmacists Association) has been the only procurement body for many years.  They played the nonprofit procurement company role in delivering this kind of drugs so that Named Patient Sales pathway is a smooth process.

Since December 2016, Turkish Social Security Institute (SGK) has been debating on delivering the drugs itself. Beginning of this year, they finalized the debates and started preparation; by changing the SGK structure as the first step. In the new structure, SGK established a new department called “Drug Procurement Department” and assigned officers to work on the new procedure and its management. The project will go live on May 2nd, 2017.

The new structure of Social Security Institute places the patient in the center. The system enables the drug to be delivered to the patients without difficulties. Ministry of Health and Social Security Institute will be cooperating in this process.

September 5th, 2016 – CarthaGenetics® will help Race Oncology  with EU market development of chemotherapy drug Bisantrene
Australian biotech
innovator Race
Oncology signs
agreement with
CarthaGenetics® for EU
market development of
chemotherapy
drug Bisantrene

CarthaGenetics® announced today that it had signed an agreement with the Australian company Race Oncology to expedite the launch of the company’s Named Patient Program (NPP) in Europe, and to distribute and sell Bisantrene under the program. Under the agreement, CarthaGenetics® will be responsible for market development and awareness of Bisantrene prior to launch and all necessary regulatory approvals to allow Bisantrene to be sold in each target NPP country. CarthaGenetics® will also be responsible for all storage, distribution, invoicing, sales and customer service of Bisantrene in each country under the Named Patient Program.
CarthaGenetics® Founder and CEO, Philippe Carteron de Balmont, said: “At CarthaGenetics, we are proud to help Race Oncology launch Bisantrene and achieve success in the European market. Named Patient access regulations in individual European countries allow patients access to innovative therapies under development. Given Bisantrene’s safety profile and clinical data, it is well-suited to a Named Patient sales Program in those countries”. The agreement will also provide Race with all the infrastructure and logistical support needed to sell Bisantrene in various European countries. In all markets outside Europe, Race Oncology is now actively pursuing licensees for Bisantrene. CarthaGenetics are experts in Named Patient Program sales in Europe,” said Managing Director, Peter Molloy. “Their expertise will help ensure Bisantrene gets to market rapidly and achieves its full sales potential.”
To that end, both companies will be attending the BioPharm America conference in Boston on 13-15 September, 2016.
For more information, contact: phcarteron@carthagenetics.com

August 10th, 2016 – CarthaGenetics® appoints new International Medical Director in Germany

Dr. Aroussi Bidani

International Medical
Director, CarthaGenetics

CarthaGenetics® is pleased to announce the appointment of Dr. Aroussi Bidani as International Medical Director, based out of the new CarthaGenetics® office in Düsseldorf, Germany.
Aroussi is graduated from the Tunis Faculty of Medicine, and has been providing a decade of medical support to CarthaGenetics® as International Medical Manager. In his new role, Dr. Aroussi will continue to provide scientific guidance to the CarthaGenetics® team, which includes a majority of medical personnel, and will share medical information about the CarthaGenetics® ongoing projects with key physicians and health authorities across Europe, Turkey and North Africa.
“Dr. Aroussi Bidani has a great personality and a passion for innovative therapy development. He did a great job establishing working relationships with doctors and health authorities across Europe, and he is now extending his reach to the German-speaking markets, his new added focus,” concludes Philippe Carteron, CEO and Founder, CarthaGenetics®.
For more information, feel free to contact him directly at: bidani@carthagenetics.com

August 10th, 2016 – CarthaGenetics® opens new office in Dusseldorf, Germany

Philippe Carteron de
Balmont, CEO and
Founder, CarthaGenetics®

CarthaGenetics® is pleased to announce the opening of a new branch office in Düsseldorf, Germany. CarthaGenetics® provides consulting international services to Orphan Drugs companies who want to expand not only in Western Europe but also in the fast-growing Turkish and North African markets. Since the company was founded back in 2004 by Philippe Carteron de Balmont, CarthaGenetics® has gradually built a solid, direct presence in places such as Algiers, Ankara, Barcelona, Lausanne, Milan, Paris and Tunis, where strong relationships have been built with physicians, governments and patients.
“With the addition of Aachen, CarthaGenetics® will expand its presence in Germany and German-speaking markets” explains Philippe de Carteron. “Germany is the largest populated country in Europe, and has thus the highest number of patients in the region. Aachen is a dynamic area with highly skilled personnel, biotechnology clusters, dynamic start-ups, and can be seen as a real gateway to neighbouring countries like Belgium and the Netherlands. This is going to be a real asset to our portfolio of biotechnology customers interested in developing new therapies in these geographies”, concludes Philippe Carteron de Balmont.
For more information, contact: phcarteron@carthagenetics.com

July 15th, 2016 – CarthaGenetics® appoints new Country Director in Turkey

Mrs. Erhan Kaya
Riveracontreras, Country
Director, Turkey

CarthaGenetics® is pleased to announce the appointment of Mrs. Erhan Kaya-Riveracontreras as Country Director for Turkey.
Historically, Turkey has been a strategic country of operation for CarthaGenetics®, where the company has invested steady efforts in best practice sharing with patients, physicians and health authorities.
Over years, CarthaGenetics®, which covers Europe, Turkey and North Africa, has hired many skilled employees in Ankara, Izmir and Istanbul. Now the company takes pride in its solid presence in Turkey, as well as its regular contributions to local biotechnology events.
This was just the right time for Erhan Kaya-Riveracontreras to embrace the challenge of managing the local CarthaGenetics® team and developing new projects in Turkey. She brings on board close to 20 years of international experience in medical, sales and marketing departments, mostly acquired at high-profile pharmaceutical companies. After obtaining her BA in Chemistry from Bosporus University, she first worked for Boehringer Ingelheim and Schering Plough in medical and sales departments. She later joined the Orphan Drugs market as one of the first employees of Genzyme Turkey. In that role, she was instrumental in establishing the rare disease concept in an orphan disease-naïve Turkey at the time. She later left Genzyme after the Sanofi acquisition. “At CarthaGenetics, we love Turkey! We have such wonderful stories and case studies of patients treated, of passionate coordination work with physicians. That’s why I am delighted to have Erhan join us today. Not only she’s bringing our CarthaGenetics team a wealth of knowledge, a fresh perspective, and eventually leadership – but this will also benefit the demanding Turkish market and our many projects in this area”, concludes Philippe Carteron de Balmont, CEO and Founder.CarthaGenetics®.
Erhan Kaya-Riveracontreras is based in Istanbul, Turkey. For more information, feel free to contact her directly at: kaya@carthagenetics.com

UPCOMING EVENTS

CarthaGenetics® at J.P. Morgan 36th Annual Healthcare Conference, San Francisco, CA – USA

San Francisco is hosting JP Morgan conference which will  be held at Westin St. Francis in San Francisco, CA from 8th to 11th January 2018. As the orphan drugs consultancy companion, We will be there. If you are interested in patients finding , early access programs in Europe or market access please contact our Director of Business Development Dr Amir Sharaf at: sharaf@carthagenetics.comand or our Market Access Director Dr Güvenç Koçkaya at: kockaya@carthagenetics.com

Full details of the conference can be found on the website:  https://www.jpmorgan.com

téléchargement

CarthaGenetics®  à la Journée Scientifique, Tunis

CarthaGenetics®a le plaisir de vous annoncer sa participation à la Journée Scientifique le 2 Décembre 2017 à l’Hôtel l’Acropole – Les Berges du Lac à Tunis, organisée par L’Association Tunisienne d’Etude des Maladies Métaboliques Héréditaires (ATEMMH)
Les principaux thèmes sont :
1- Convulsions de l’enfant, retard mental : quand penser à une maladie héréditaire du métabolisme
2- Autisme dans les troubles métaboliques
3- Cas cliniques en ophtalmologie métabolique

Pour rencontrer notre CEO, Philippe Carteron de Balmont, merci de prendre contact avec lui à phcarteron@carthagenetics.com

ATEMMH

Meet CarthaGenetics® at Bioalps Networking Day 2017, Lausanne
CarthaGenetics® will attend BioAlps Networking Day 2017 November 21, 2017.  If you would like to arrange a meeting with us, do not hesitate to contact our CEO, Philippe Carteron de Balmont at phcarteron@carthagenetics.com
Full details of the congress can be found on the website:

LogoBND2017-01

Meet CarthaGenetics® at SEPD Symposium

CarthaGenetics® will attend SEPD Symposium on Early Access to Innovative Treatments in Istanbul, Turkey on 8th December 2017.  Philippe Carteron will give a speech about Examples of Early Access especially from France, Italy & Spain. If you would like to arrange a meeting with us, do not hesitate to contact Philippe Carteron at  phcarteron@carthagenetics.com,

People can live healthier and longer with innovative treatments. According to the studies, access to innovative treatments should be as early as possible so that the benefit of the individual can be maximized. On the other hand, the cost of access to innovative treatments is increasing every year. Therefore, these costs, especially in countries like Turkey where the health system is financed by the government, become even more important for a sustainable health system.
In this context, “Early Access to Innovative Treatments Symposium” will be held at Boğaziçi University Campus of Istanbul on December 8, 2017 by the Association of Health Economics and Policy (SEPD), with the participation of patient groups, health workers, health service providers, academia and public employees.

Full details of the congress can be found on the website: http://sempozyum2017.sepd.org.tr/

sepd_logo

Meet CarthaGenetics® at the 3rd International Primary Immunodeficiencies Congress, Dubai

CarthaGenetics® will attend the 3rd International Primary Immunodeficiencies (IPIC 2017) Congress in Dubai, UAE from 8th to 10th November.  If you would like to arrange a meeting with us, do not hesitate to contact Filiz Cavus at  cavus@carthagenetics.com

Full details of the congress can be found on the website: https://www.ipic2017.com/

logo-ipic2017

Meet CarthaGenetics® at ISPOR 20th Annual European Meeting

CarthaGenetics® will attend is going to attend to ISPOR 20th Annual European Meeting from 4 to 68November, 2017 in Glasgow, Scotland. The Market Access Team in the Kitchen is going to present posters titled as “MOBILE CARDIAC MONITORIZATION IS A COST-EFFECTIVE TOOL FOR THE DIAGNOSIS AND MANAGEMENT OF ATRIAL FIBRILLATION COMPARED TO HOLTER: A COST EFFECTIVENESS STUDY IN TURKEY”, “OVERVIEW OF INNOVATIVE MEDICINE SECTOR IN TURKEY” and  “INCREASING TREND ON TURKISH UN-LICENCED MEDICINE MARKET : A GENERAL OVERVIEW ANALYSIS”.
Keep track, keep contact. For further questions : kockaya@carthagenetics.comsharaf@carthagenetics.com

https://www.ispor.org/Event/index/2017Glasgow

2017GlasgowBanner300x250
Meet CarthaGenetics® at CPhI Worlwide

CarthaGenetics® will attend CPhI Worlwide from 24th to 26th October, 2017 in Messe Frankfurt, Germany. If you would like to arrange a meeting with us, do not hesitate to contact Dr. Aroussi Bidani at  bidani@carthagenetics.com

website: https://www.cphi.com/europe/

CPHI

Meet CarthaGenetics® at the 3rd Pediatric Genetics Symposium, Antalya, Turkey

CarthaGenetics® will attend the 3rd Pediatric Genetics Symposium from 11th to 13th October 2017 in Antalya, Turkey. If you would like to arrange a meeting with us, do not hesitate to contact Filiz Cavus at  cavus@carthagenetics.com

Full details of the congress can be found on the website: http://www.cocukgenetik2017.com/

 

topo

Meet CarthaGenetics® at 2017 Cell & Gene Meeting on the MESA, la Jolla, CA, USA, 4-6 October 2017

The Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. Philippe Carteron de Balmont, our CEO, will participate to this exciting event. Contact us if you would like us to arrange for a meeting with Philippe  at azzouzi@carthagenetics.com.

Full details on the conference can be found on the meeting website: www.meetingonthemesa.com

CGMOM_ARM_Web_Banner_2017_580x280

September 26th, 2017 – Meet CarthaGenetics® at BioPharm America

CarthaGenetics® will attend BioPharm America from 26th to 28th September 2017 in Sheraton hotel, Boston. If you would like to arrange a meeting with us, do not hesitate to contact our CEO Philippe Carteron de Balmont at phcarteron@carthagenetics.com or Dr. Amir sharaf at  sharaf@carthagenetics.com

biopharm-america-partnering-conference-info

Meet CarthaGenetics® at Drug Agencies and their Roles in the Promotion of R & D in Barcelona tomorrow, September 14th, 2017

Member of ASEBIO, The Spanish Bioindustry Association, CarthaGenetics® will attend this confernece on 14th September 2017 in Auditorio Del Parque de Investigacion Biomédica de Barcelona (C/Doctor Aiguader, 88), Barcelona Spain.  If you would like to arrange a meeting with us, do not hesitate to contact Dr Samira Benmansour at  at benmansour@carthagenetics.com .

http://www.asebio.com/en/event_item.cfm?iid=aemps_barcelonaimage_305024453627

PAST EVENTS

July 8th, 2017 – Meet CarthaGenetics® at the World Health Economics Congress

iHEA is going to organize World Health Economics Congress between 8-11 July 2017 in Boston, USA. Topic of congress is set as “Revolutions in the Economics of Health Systems”. The study titled as “Impact of Health Policies on Catastrophic Health Expenditures in Turkey” which was conducted by Guvenc Kockaya, MD,MSc,PhD.

Berna Tuncay, Aysun Aygun and Julide Yildirim will be presented as verbal presentation on 10 July 2017, 2.45-4.15 pm in “High/Catastrophic Health Cost” session, HAR-312 room.
In additonal, “Hospital Ownership” session on 9 July 2017, 2.45-4.15 pm in HAR-324 room will be lead by Guvenc Kockaya, MD,MSc,PhD.
CarthaGenetics® will be represented in the meeting as well. Please contact for further questions and discussions on kockaya@carthagenetics.com
Boston
June 12th, 2017 – Meet CarthaGenetics® at SFEIM & CETL

CarthaGenetics® will attend SFEIM & CETL Congress from 12th to 14th June 2017 in Institut Culturel Bernard Magrez; Bordeaux, France. If you would like to arrange a meeting with us, do not hesitate to contact our CEO Philippe Carteron de Balmont at phcarteron@carthagenetics.com or Mr. Haythem Ammar at  ammar@carthagenetics.com

http://comnco.net/evenement/reunions-sfeim-cetl/

SFEIM

 

 

 

 

 

 

 

June 8th, 2017 – Meet CarthaGenetics®, Key Sponsor of REFRESH 2017

CarthaGenetics® will be a Key Event Sponsor of REFRESH 2017, the one-day annual conference organized by Labiotech.eu, Europe’s leading digital media for biotechnologies. CarthaGenetics® will naturally attend the 3rd edition of this event, held in Berlin, Germany on June 8th, 2017. If you would like to arrange a meeting with us, please contact us at our respective e-mail addresses:

–         Philippe Carteron de Balmont at phcarteron@carthagenetics.com,

–         Pascal Cerruti at pascal.cerruti@carthagenetics.com,

–         Dr. Aroussi Bidani at bidani@carthagenetics.com

More information at: http://labiotech.eu/refresh/attendees/

Refresh 2017

May 14th, 2017 – Meet CarthaGenetics® at the 18th International Pharmaceutical Forum

CarthaGenetics® will attend the 18th International Pharmaceutical Forum from 14th to 16th May 2017 in Centre International Conferences, Algeria. If you would like to arrange a meeting with us, do not hesitate to contact Ms Imane BELALA at belala@carthagenetics.com

FPI ALGER

May 7th, 2017 – Meet CarthaGenetics® at the 3rd Annual Congress of the ESVM and 23rd IUA EuroChap Congress

CarthaGenetics® will attend the 3rd Annual Congress of the ESVM and 23rd IUA EuroChap Congress from 7th to 9th May 2017 in Graz, Austria . If you would like to arrange a meeting with us, do not hesitate to contact M. Riccardo Lang , at lang@carthagenetics.com or Dr. Aroussi Bidani at bidani@carthagenetics.com

https://mi.wikonect.de/forms/ESVM2017G.doESVMCongress

 May 5-6th, meet us in Tunisia, at the 11th Tunisian Congress of Inborn Errors of Metabolism

CarthaGenetics® will participate to the “11e Ecole Métabolique”, organized by the “‘Association Tunisienne d’Etudes des Maladies Métaboliques Héréditaires” (ATEMMH), on May 5-6, Hôtel Russelior, Hammamet, Tunisia. Do not hesitate to contact our CEO there, Philippe Carteron de Balmont (phcarteron@carthagenetics.com)

unnamed

May 4th, 2017 – Meet CarthaGenetics® at the Swiss Biotech Day 2017

CarthaGenetics® will attend the SWISS BIOTECH DAY, on May 4th, at Congress Center Basel, Switzerland. If you would like to arrange a meeting with us, do not hesitate to contact our CEO there, Philippe Carteron de Balmont , at phcarteron@carthagenetics.com

A football stadium and shopping centre combined: St. Jakob-Park was built by renowned architects Herzog & de Meuron. -- Fussballstadion und Shopping-Center in einem: der St. Jakob-Park wurde vom renommierten Architektenduo Herzog & de Meuron erbaut.

April 26th, 2017 – Meet CarthaGenetics® at IVEK 3rd International Convention of Pharmaceuticals and Pharmacies

CarthaGenetics® is participating in IVEK 3rd International Convention of Pharmaceuticals  and Pharmacies from 26th to 29th April in WOW Istanbul Hotel & Convention Center, Istanbul, Turkey.  If you would like to arrange a meeting with us, do not hesitate to contact Filiz Cavus at: cavus@carthagenetics.com

http://ivekkongre.com/

IVEK

April 23rd, 2017 – Meet CarthaGenetics® at the 7th meeting of the French Angiogenesis Society

CarthaGenetics® is participating in the 7th meeting of the French Angiogenesis Society from 23rd to 25th April in Toulouse, France.  If you would like to arrange a meeting with us, do not hesitate to contact Haythem Ammar at: ammar@carthagenetics.comlogo-transparent-150x150

April 19th, 2017 – Meet CarthaGenetics® at the 19th National Pediatric Neurology Congress

CarthaGenetics® is participating in the 19th National Pediatric Neurology Congress at Cornelia Diamond Hotel Belek, in Antalya, Turkey, between April 19-23. If you would like to arrange a meeting with us, do not hesitate to contact Filiz Cavus at: cavus@carthagenetics.com or Mustapha Aydin at:  aydin@carthagenetics.com

http://www.pednoro2017.org

unnamed

March 30th, 2017 – Meet CarthaGenetics® at the Pluripotent Stem Cells and Gene editing Symposium

CarthaGenetics® is participating to the Pluripotent Stem Cells and Gene editing Symposium, at University of Los Andes, Santiago, Chile, on March 30-31.  If you would like to arrange a meeting with us, do not hesitate to contact our CEO there, Philippe Carteron de Balmont , at: phcarteron@carthagenetics.com

t2

March 23rd, 2017 – Meet CarthaGenetics® at the 2nd Rare Diseases & Orphan Drugs Symposium

Carthagenetics® will attend the 2nd Rare Diseases & Orphan Drugs Symposium on 23 & 24 March, 2017 in Ankara, Turkey. If you would like to arrange a one-to-one meeting with us, please send an email to  Erhan Kaya Riveraconteras at: kaya@carthagenetics.com or Mr. Guvenc Kockaya at: kockaya@carthagenetics.com

Mr. Kockaya will present in the panel named as “Regulatury, Reimbursement and Budget Process for Orphan Medicines” on 24th March at 13.00-15.30, the presentation will focus on “possible budget impact of orphan medicines”.

http://www.nadirhastaliklarsempozyumu2017.org/default.asp?kid=1&alt_kid=0&alt_kid1=0

Untitled-1

 

March 20th, 2017 – Meet CarthaGenetics® at Bio-Europe Spring

Carthagenetics® will attend Bio-Europe Spring on 20 – 22 March, 2017 in Barcelona, Spain. If you would like to arrange a one-to-one meeting with us, please send an email to our CEO, Philippe Carteron de Balmont (phcarteron@carthagenetics.com)

Bio-europe-spring-logo-01-4170ea43ae49c293bf1243c5b6d13682

March 18th, 2017 – Meet CarthaGenetics® at 10ème journée nationale pharmaceutique

Carthagenetics® will attend 10ème journée nationale pharmaceutique on 18th March, 2017 at Hotel El Aurassi, Algeria: « LE PHARMACIEN & LA POLITIQUE NATIONALE DU MEDICAMENT » If you would like to arrange a one-to-one meeting with us, please send an email to Ms Imane Belala (belala@carthagenetics.com)

unnamed

 February 23rd, 2017 – Meet CarthaGenetics® at Global Health Event “A conversation with Ruth Dreifuss, High-Level Panel on Access to Medicine”

Carthagenetics® will attend this event on February 23rd, 2017 in Maison de la Paix, Geneva, Switzerland. If you would like to arrange a one-to-one meeting with us, please send an email to our CEO, Philippe Carteron de Balmont (phcarteron@carthagenetics.com)

http://graduateinstitute.ch/globalhealth-event

February 13th, 2017 – Meet CarthaGenetics® at the 13th Annual World Symposium

CarthaGenetics® will attend the 13th Annual World Symposium, on February 13 – 17, 2017 in San Diego, California. If you would like to arrange a meeting with us please contact: Philippe Carteron at phcarteron@carthagenetics.com or Erhan Kaya at kaya@carthagenetics.com

worldsymposium-short

February 10th, 2017 – Meet CarthaGenetics® at Rare Diseases International Policy Event

CarthaGenetics® will be attending the  Rare Diseases International Policy Event on February 10th, 2017 in Switzerland, Geneva. If you would like to arrange a meeting with us during the congress, please contact: Philippe Carteron de Balmont, CEO,  at: phcarteron@carthagenetics.com

rare-disease-geneva

February 8th, 2017 – Meet CarthaGenetics® at the 3rd IRDiRC Conference
Carthagenetics® will attend the 3rd IRDiRC Conference on February 8th & 9th, 2017 in Paris, France. If you would like to arrange a one-to-one meeting with us, please send an email to Doctor Amir SHARAF (sharaf@carthagenetics.com) or Haythem AMMAR (ammar@carthagenetics.com)

IRDiRC-2017_Save-the-date_low-res

December 21st, 2016 – Meet CarthaGenetics® at 13th Pharmaceutical Congress of Turkey

CarthaGenetics® will be attending the 13th Pharmacist Congress of the Turkish Pharmacist Association (TEB) in Istanbul, Turkey from December 21st till December 24th, 2016. This is the major congress for the topics related with pharmacy and pharmacist in Turkey. Turkish and international speakers from government, academy and private sector will present recent developments, updates and new approaches. If you would like to arrange a meeting with us during the congress, please contact: Erhan Kaya Riveraconteras at: kaya@carthagenetics.com, Filiz Cavus at: cavus@carthagenetics.com , or Guvenc Kockaya at:  kockaya@carthagenetics.com

afis_02

November 29th, 2016 – Meet CarthaGenetics® at BIOLATAM 2016

CarthaGenetics® will be attending the 3rd Annual International Partening Conference BIOLATAM in San Juan, Puerto Rico  on November 29th  & 30th, 2016. If you would like to arrange a meeting with us during the conference, please contact Philippe Carteron de Balmont, CEO, at: phcarteron@carthagenetics.com

biolatam-logo-01-a4cadbf537535d995e24533162000e72

November 25th, 2016 – Meet CarthaGenetics® at  52nd  Annual Congress of the Turkish Neurological Society

CarthaGenetics® will be attending the 52nd Annual Congress of the Turkish Neurological Society in Antalya, Turkey, from November 25th till December 1st, 2016. If you would like to arrange a meeting with us during the congress, please contact: Aroussi Bidani at: bidani@carthagenetics.com, Filiz Cavus at: cavus@carthagenetics.com , or Mustapha Aydin at:  aydin@carthagenetics.com

52-turkish-congress

 November 24th, 2016 –  9th Pediatric Nephrology Congress in Antalya

CarthaGenetics® attended the 9th Pediatric Nephrology Congress held in Antalya, Turkey from 24th to 27th  November, 2016. The congress was organized by the Pediatric Nephrology Association. Both Turkish and European speakers have presented the conventional and novel treatment approaches in kidney diseases in children. 

nefroloji-kongressi

November 24th, 2016 – Meet CarthaGenetics® at Refresh Europe 2016 in Paris

CarthaGenetics® will be attending Refresh Europe 2016 in Paris, France, on November 24th, 2016. Organized by Labiotech, this is Europe’s most refreshing biotech conference in its second edition.Come to get a deep insight into tomorrow’s Biotech trends in a dynamic and modern way, and meet with 250 of Europe’s Biotech leaders, innovators and enthusiasts. To arrange a short meeting with us at the event, please contact Philippe Carteron de Balmont, CEO, at: phcarteron@carthagenetics.com and connect to this event at: http://labiotech.eu/refresh/

labiotech_refresh_paris_header

November 7th, 2016 – Meet CarthaGenetics® at BIO-Europe 2016 Cologne

CarthaGenetics® will be attending BIO-Europe 2016 in Cologne, Germany, on November 7-9th, 2016. This is the 22nd annual BIO-Europe event, the largest biotechnology partnering conference held in Europe. Over 3,500 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and deal makers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. If you would like to arrange a meeting with us during the conference, please contact Philippe Carteron de Balmont, CEO, at: phcarteron@carthagenetics.com or through the web-based partnering system at: https://ebdgroup.knect365.com/bioeurope/

bioeurope-cologne-2016_banner

November 2nd, 2016 – Meet CarthaGenetics® at Bio-Alps Networking Day 2016 in Geneva

CarthaGenetics® will be attending the Bio-Alps Networking Day 2016 in Geneva, Switzerland, on November 2nd, 2016. To arrange a short meeting with us at the event or after the event, please contact Philippe Carteron de Balmont, CEO, at: phcarteron@carthagenetics.com and connect to this event at: http://m.bioalps.org/biotechnology/bioalps-networking-2016-2016-1628.html

bioalpsnetworkingdaylogo

October 4th , 2016 – Meet CarthaGenetics® at CPHI Worldwide 2016

CarthaGenetics® will be attending CPHI Worldwide 2016 Congress in Barcelona, Spain from October 4th-6th, 2016. If you would like to arrange a meeting with us during the conference, please contact Philippe Carteron de Balmont, CEO, at: phcarteron@carthagenetics.com

September 28th, 2016 – Meet CarthaGenetics® at BioSpain 2016

CarthaGenetics® will be attending the BioSpain 2016 Congress in Bilbao, Spain, from September 28th-30th, 2016. If you would like to arrange a meeting with us during the conference, please contact Naciba Zetchi, Area Director, Spain and Portugal, at: Zetchi@carthagenetics.com

September 13th, 2016 – Meet CarthaGenetics® at BioPharm America 2016

CarthaGenetics® will be attending the BioPharm America 2016 Congress in Boston, USA, from September 13th-15th, 2016. If you would like to arrange a meeting with us during the conference, please contact Philippe Carteron de Balmont, CEO, at phcarteron@carthagenetics.com

September 6th, 2016 – Meet CarthaGenetics® at SSIEM Rome 2016

CarthaGenetics® will be attending the annual Symposium SSIEM in Rome, Italy, from September 6th-9th, 2016. If you would like to arrange a meeting with us during the conference, please contact Philippe Carteron de Balmont, CEO, at: phcarteron@carthagenetics.com

June 30th, 2016 – Meet CarthaGenetics® at MPS 2016 Bonn, Germany

CarthaGenetics® will be attending the MPS2016 congress in Bonn, Germany on July 13th-16th, 2016. If you would like to arrange a meeting with us during the conference, please contact Philippe Carteron de Balmont, CEO, at: phcarteron@carthagenetics.com

June 10th, 2016 – Meet CarthaGenetics® at Les Journées de Printemps   SFEIM 2016, Grenoble

CarthaGenetics® will be attending Les Journées de Printemps de la SFEIM (Société Française des Erreurs Innées du Métabolisme) in Grenoble, France on June 17th-18th, 2016 If you would like to arrange a meeting with us during the conference, please contact Philippe Carteron de Balmont, CEO, at: phcarteron@carthagenetics.com

May 3rd, 2016 – Meet CarthaGenetics® at Labiotech Refresh 2016 in Berlin

CarthaGenetics® will be attending the Labiotech Refresh 2016 in Berlin, Germany on April, 24th, 2016. If you would like to arrange a meeting with us during the conference, please contact Philippe Carteron de Balmont, CEO, at: phcarteron@carthagenetics.com

April 10th, 2016 – Meet CarthaGenetics® at the World Orphan Drugs Congress 2016 USA

CarthaGenetics® will be attending the World Orphan Drugs Congress 2016 USA, held at The Washington Hilton, Washington DC, from April 20th– 22nd, 2016. If you would like to arrange a meeting with us during the conference, please contact Philippe Carteron de Balmont, CEO, at: phcarteron@carthagenetics.com

April 8th, 2016 – Meet CarthaGenetics® at Lizozomal 2016 in Bodrum, Turkey

CarthaGenetics® will be attending Lizozomal 2016 in Bodrum, Turkey, from April 14th to 18th, 2016. If you would like to arrange a meeting with us during the conference, please contact Philippe Carteron de Balmont, CEO, at: phcarteron@carthagenetics.com